Sign In
Buy LXRX
$2.31
-0.0300 (-1.28%)
At Close: Jul 31, 2026
THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will hold a conference call and webcast on Monday, March 3, 2025 at 8:
Data reinforce unique clinical advantages of sotagliflozin Published study is aligned with research presented in December 2024 at the American Society of Hematology showing clinical benefits of sota
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
08:00am, Tuesday, 21'st Jan 2025
Event will feature insights on LX9211, Lexicon's novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP Event will feature insights on LX9211, Lexicon's novel, i
Lexicon Appoints Scott Coiante as Chief Financial Officer
08:00am, Thursday, 02'nd Jan 2025
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial offic
US FDA declines to approve Lexicon Pharma's add-on diabetes drug
04:46pm, Friday, 20'th Dec 2024
The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
04:30pm, Friday, 20'th Dec 2024
THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Admini
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
08:00am, Tuesday, 26'th Nov 2024
Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule
Lexicon Pharmaceuticals to Participate in December Investor Conferences
04:15pm, Monday, 25'th Nov 2024
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon's chief executive officer an
Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development
07:47am, Friday, 22'nd Nov 2024
Lexicon Pharmaceuticals said on Friday it would reduce its workforce by about 60%, effective Dec. 31, to eliminate commercial activities and focus on drug development.
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
07:32am, Friday, 22'nd Nov 2024
Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions
Lexicon Appoints Ivan H. Cheung to Board of Directors
04:05pm, Wednesday, 20'th Nov 2024
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors.
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript
08:39pm, Tuesday, 12'th Nov 2024
Start Time: 17:00 January 1, 0000 5:55 PM ET Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q3 2024 Earnings Call November 12, 2024, 17:00 PM ET Company Participants Mike Exton - CEO and Director Tom Ga
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates
06:26pm, Tuesday, 12'th Nov 2024
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago.
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
04:05pm, Tuesday, 12'th Nov 2024
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
08:00am, Wednesday, 06'th Nov 2024
THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference. Lexicon man
